Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 2163053, 14 pages
https://doi.org/10.1155/2017/2163053
Review Article

A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson’s Disease

1Department of Neurology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Neurology, Zhengzhou People’s Hospital, Zhengzhou 450003, China

Correspondence should be addressed to Shu-ling Zhang; moc.361@71366lsz and Guo-qing Zheng; moc.uhos@gnehz_qg

Received 23 November 2016; Revised 24 January 2017; Accepted 14 February 2017; Published 13 March 2017

Academic Editor: Elena Azzini

Copyright © 2017 Liang Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. E. Alexander, “Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder,” Dialogues in Clinical Neuroscience, vol. 6, no. 3, pp. 259–280, 2004. View at Google Scholar
  2. M. Löhle and H. Reichmann, “Clinical neuroprotection in Parkinson's disease—still waiting for the breakthrough,” Journal of the Neurological Sciences, vol. 289, no. 1-2, pp. 104–114, 2010. View at Publisher · View at Google Scholar
  3. P. Calabresi, M. D. Filippo, V. Ghiglieri, N. Tambasco, and B. Picconi, “Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap,” The Lancet Neurology, vol. 9, no. 11, pp. 1106–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. A. Zesiewicz and M. L. Evatt, “Potential influences of complementary therapy on motor and non-motor complications in parkinsons disease,” CNS Drugs, vol. 23, no. 10, pp. 817–835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Zheng, “Therapeutic History of Parkinson's Disease in Chinese Medical Treatises,” The Journal of Alternative and Complementary Medicine, vol. 15, no. 11, pp. 1223–1230, 2009. View at Publisher · View at Google Scholar
  6. S.-Y. Nah, D.-H. Kim, and H. Rhim, “Ginsenosides: are any of them candidates for drugs acting on the central nervous system?” CNS Drug Reviews, vol. 13, no. 4, pp. 381–404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Lu, Q. Yao, and C. Chen, “Ginseng compounds: an update on their molecular mechanisms and medical applications,” Current Vascular Pharmacology, vol. 7, no. 3, pp. 293–302, 2009. View at Publisher · View at Google Scholar
  8. K. Leung and A. Wong, “Pharmacology of ginsenosides: a literature review,” Chinese Medicine, vol. 5, no. 1, article no. 20, 2010. View at Publisher · View at Google Scholar
  9. B. Jiang, Z. Xiong, J. Yang et al., “Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus,” British Journal of Pharmacology, vol. 166, no. 6, pp. 1872–1887, 2012. View at Publisher · View at Google Scholar
  10. H. J. Kim, P. Kim, and C. Y. Shin, “A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system,” Journal of Ginseng Research, vol. 37, no. 1, pp. 8–29, 2013. View at Publisher · View at Google Scholar
  11. K. Radad, G. Gille, L. Liu, and W.-D. Rausch, “Use of ginseng in medicine with emphasis on neurodegenerative disorders,” Journal of Pharmacological Sciences, vol. 100, no. 3, pp. 175–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. H. B. van der Worp, D. W. Howells, E. S. Sena et al., “Can animal models of disease reliably inform human studies?” PLoS medicine, vol. 7, no. 3, Article ID e1000245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. R. Macleod, T. O'Collins, D. W. Howells, and G. A. Donnan, “Pooling of animal experimental data reveals influence of study design and publication bias,” Stroke, vol. 35, no. 5, pp. 1203–1208, 2004. View at Publisher · View at Google Scholar
  14. H. M. Vesterinen, E. S. Sena, K. J. Egan et al., “Meta-analysis of data from animal studies: a practical guide,” Journal of Neuroscience Methods, vol. 221, pp. 92–102, 2014. View at Publisher · View at Google Scholar
  15. H. W. E. Zhang, Z. X. I. Lin, C. Xu, C. Leung, and L. S. U. Chan, “Astragalus (a traditional Chinese medicine) for treating chronic kidney disease,” The Cochrane Database of Systematic Reviews, vol. 10, Article ID CD008369, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Heng, Q.-S. Zhang, Z. Mu, J.-F. Hu, Y.-H. Yuan, and N.-H. Chen, “Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra,” Toxicology Letters, vol. 243, pp. 7–21, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Jiang, Z. Wang, Y. Jiang, M. Lu, and X. Li, “Ginsenoside Rg1 ameliorates motor function in an animal model of Parkinson's disease,” Pharmacology, vol. 96, no. 1-2, pp. 25–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. T.-T. Zhou, G. Zu, X. Wang et al., “Immunomodulatory and neuroprotective effects of ginsenoside Rg1 in the MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) -induced mouse model of Parkinson's disease,” International Immunopharmacology, vol. 29, no. 2, pp. 334–343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. X.-C. Chen, Y.-C. Zhou, Y. Chen, Y.-G. Zhu, F. Fang, and L.-M. Chen, “Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress,” Acta Pharmacologica Sinica, vol. 26, no. 1, pp. 56–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. X.-C. Chen, Y. Chen, Y.-G. Zhu, F. Fang, and L.-M. Chen, “Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons,” Acta Pharmacologica Sinica, vol. 23, no. 9, pp. 829–834, 2002. View at Google Scholar · View at Scopus
  21. J. B. Wei, F. Yang, and S. X. Wang, “Influence of Ginsenoside Rg1 on expression of erythropoietin-producing hepatocellular cell line A4 in substantia nigras of mice with Parkinson's disease induced by 1-methy-4-pheny-1,2,3,6-tetrahy-dro-pyrdine,” Journal of Xinxiang Medical University, vol. 32, no. 5, pp. 404–407, 2015. View at Google Scholar
  22. S. X. Wang, F. X. Zhu, P. Y. Li, and Y. Duan, “Effects of ginsenoside Rgl on apoptosis of dopamine neurons, expression l,TH and P-c-Jun in substantia nigra of mice with Parkinson,” Journal of Zhengzhou University, vol. 50, no. 2, pp. 176–180, 2015. View at Google Scholar
  23. F. X. Zhu, Y. Duan, P. Y. Li, and S. X. Wang, “Effect of ginsenoside Rg1 on the expressions of tyrosine hydroxylase, ephrinB2 and phosphorylated c-Jun in substantia nigra of mice with Parkinson's disease,” Journal of Xinxiang Medical University, vol. 31, no. 10, pp. 781–785, 2014. View at Google Scholar
  24. Q. Wang, H. Zhang, M. Liu et al., “Influence of ginsenoside Rg1 in expressions of FADD and FLIP in substantia nigra of Parkinson's disease model mice,” Journal of Jilin University Medicine Edition, vol. 40, no. 5, pp. 962–966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Yan, L. Wu, D. D. Xue, X. Q. Gao, and W. F. Chen, “Effects of Gesenoside Rg1 and insulin-like growth factor-I on dopaminergic neurons in Parkinson's disease mice,” Acta Academic Medicine QingDao University, vol. 50, no. 4, pp. 283–285, 2014. View at Google Scholar
  26. J. L. R. Liu, L. Li, Y. X. Zhang, and Z. F. Zhang, “The protective effect of Ginsenoside Rg1 on nerves in the mice model of Parkinson's disease,” Clinical Medicine of China, vol. 24, no. 9, pp. 898–900, 2008. View at Google Scholar
  27. G. J. Yang, J. P. Zhang, and Q. Y. Li, “Effect of ginsenoside Rg1 on neural stem cells in subventricular zone in modeled mice of Parkinson's disease,” Sichuan Journal of Physiological Sciences, vol. 31, no. 1, pp. 17–19, 2009. View at Google Scholar
  28. G. Z. Ji, The experimental research for evaluating mice's dopaminergic neurons function by 99mTC-TRODAT-1 [Postgraduates' degree Thesis], 2008.
  29. Q. Wang, H. Zheng, Z.-F. Zhang, and Y.-X. Zhang, “Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway,” Journal of Southern Medical University, vol. 28, no. 9, pp. 1594–1598, 2008. View at Google Scholar · View at Scopus
  30. H. D. Yang, Neurprotective effects of Ginsenoside Rg1 on the dopaminergic neuron loss in the substantia nigra of MPTP-treated C57BL6 mice [Postgraduates' degree Thesis], 2007.
  31. Y. C. Zhou, Y. G. Zhu, F. Fang, and L. M. Chen, “The influence of Ginsenoside Rg1 on JNK signaling cascade in PD mouse substantia nigra neurons,” Acta Anatomica Sinica, vol. 34, no. 5, pp. 477–481, 2003. View at Google Scholar
  32. G. G. Meng, Z. F. Zhang, X. J. Huan, Z. F. Wei, R. Li, and Y. X. Zhang, “Ginsenside Rgl protects the dopaminergic neurolls in substantia nigra against the apoptosis via downregulate the endoplasmic reticulum stress proteins expressions in the MPTP-induced Parkinson's disease mouse model,” Chinese Journal of Anatomy, vol. 34, no. 3, pp. 358–361, 2011. View at Google Scholar
  33. F. W. Yang, Influence of Ginsenside Rg1 on expressions of EphB6 and ephrinB1 in substantia nigra of mice with Parkinson's disease induced by MPTP [Postgraduates' degree Thesis], 2014.
  34. Y. S. Wang, Y. X. Zhang, S. P. Wei, Z. F. Zhang, and Q. Y. Tian, “Influence of Ginsenoside Rg1 on p-c-Jun and COX-2 expression insubstantia nigra of the MPTP mouse model of subacute Parkinson's disease,” Chinese Journal of Neuroanatomy, vol. 25, no. 4, pp. 432–436, 2009. View at Google Scholar
  35. L. Xu, W. Chen, and M. Wong, “Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway,” British Journal of Pharmacology, vol. 158, no. 3, pp. 738–748, 2009. View at Publisher · View at Google Scholar
  36. J. Jie, Study of neuroprotective effects of antioxidant Ginsenoside Rg1 on the Parkinson rats [Postgraduates' degree Thesis], 2010.
  37. L. Xu, L.-X. Liu, and W.-F. Chen, “Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1,” Journal of Chinese Materia Medica, vol. 33, no. 15, pp. 1856–1859, 2008. View at Google Scholar · View at Scopus
  38. L. Z. M. Xu and W. F. Chen, “Neuroprotective effect of ginsenoside Rg1 on dopaminergic neurons and blocking effect of ICI182, 780,” Journal of Shanxi Medical University, vol. 38, no. 8, pp. 677–681, 2007. View at Google Scholar
  39. T. Zhou, G. Zu, X. Zhang et al., “Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson's disease,” Neuropharmacology, vol. 101, pp. 480–489, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. X.-C. Sun, X.-F. Ren, L. Chen, X.-Q. Gao, J.-X. Xie, and W.-F. Chen, “Glucocorticoid receptor is involved in the neuroprotective effect of ginsenoside Rg1 against inflammation-induced dopaminergic neuronal degeneration in substantia nigra,” Journal of Steroid Biochemistry and Molecular Biology, vol. 155, pp. 94–103, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. G. H. Guyatt, A. D. Oxman, V. Montori et al., “GRADE guidelines: 5. Rating the quality of evidence—publication bias,” Journal of Clinical Epidemiology, vol. 64, no. 12, pp. 1277–1282, 2011. View at Publisher · View at Google Scholar
  42. E. D. M. Rooke, H. M. Vesterinen, E. S. Sena, K. J. Egan, and M. R. Macleod, “Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis,” Parkinsonism and Related Disorders, vol. 17, no. 5, pp. 313–320, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. B. C. Kahan, S. Cro, C. J. Doré et al., “Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials,” Trials, vol. 15, no. 1, article no. 456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Held, “On the impact of sample size calculation and power in clinical research,” Praxis, vol. 103, no. 20, pp. 1197–1201, 2014. View at Publisher · View at Google Scholar
  45. K. F. Schulz and D. A. Grimes, “Sample size calculations in randomised trials: mandatory and mystical,” The Lancet, vol. 365, no. 9467, pp. 1348–1353, 2005. View at Publisher · View at Google Scholar
  46. D. G. Hackam, “Translating animal research into clinical benefit,” British Medical Journal (Clinical Research Edition), vol. 334, no. 7586, pp. 163–164, 2007. View at Publisher · View at Google Scholar
  47. D. G. Hackam and D. A. Redelmeier, “Translation of research evidence from animals to humans,” JAMA, vol. 296, no. 14, pp. 1727–1732, 2006. View at Publisher · View at Google Scholar
  48. Y. Takino, “Studies on the pharmacodynamics of ginsenoside-Rg1, -Rb1 and -Rb2 in rats,” Yakugaku Zasshi, vol. 114, no. 8, pp. 550–564, 1994. View at Google Scholar · View at Scopus
  49. Y. Zhang, L. Lin, G. Y. Liu, J. X. Liu, and T. Li, “Pharmacokinetics and brain distribution of ginsenosides after administration of Sailuotong,” China Journal of Chinese Materia Medica, vol. 39, no. 2, pp. 316–321, 2014 (Chinese). View at Publisher · View at Google Scholar
  50. H. Liu, J. Yang, F. Du et al., “Absorption and disposition of ginsenosides after oral administration of panax notoginseng extract to rats,” Drug Metabolism and Disposition, vol. 37, no. 12, pp. 2290–2298, 2009. View at Publisher · View at Google Scholar
  51. M. Karikura, T. Miyase, H. Tanizawa, Y. Takino, T. Taniyama, and T. Hayashi, “Studies on absorption, distribution, excretion and metabolism of Ginseng saponins. V. The decomposition products of ginsenoside Rb2 in the large intestine of rats,” Chemical and Pharmaceutical Bulletin, vol. 38, no. 10, pp. 2859–2861, 1990. View at Publisher · View at Google Scholar · View at Scopus
  52. X. X. Wen, “Treating 68 cases of tremble of Qixue Kuixu type with the Renshen Yangrong decoction,” Clinical Journal of Chinese Medicine, vol. 5, no. 3, p. 67, 2013. View at Publisher · View at Google Scholar
  53. D. G. Wang, “Clinical observation of Ginseng Guipi decoction on elderly patients of deficiency of qi and blood type with Parkinson's disease,” Guiding Journal of Traditional Chinese Medicine and Pharmacy, vol. 20, no. 6, pp. 126–127, 2014. View at Google Scholar
  54. J. Wei, W. Yang, S. Yin, C. Wang, Y. Wang, and G. Zheng, “The quality of reporting of randomized controlled trials of electroacupuncture for stroke,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, article no. 512, 2016. View at Publisher · View at Google Scholar